Yerlikaya Seda, Broger Tobias, MacLean Emily, Pai Madhukar, Denkinger Claudia M
FIND, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
FIND, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Int J Infect Dis. 2017 Mar;56:253-257. doi: 10.1016/j.ijid.2017.01.025. Epub 2017 Jan 31.
New diagnostic innovations for tuberculosis (TB), including point-of-care solutions, are critical to reach the goals of the End TB Strategy. However, despite decades of research, numerous reports on new biomarker candidates, and significant investment, no well-performing, simple and rapid TB diagnostic test is yet available on the market, and the search for accurate, non-DNA biomarkers remains a priority. To help overcome this 'biomarker pipeline problem', FIND and partners are working on the development of a well-curated and user-friendly TB biomarker database. The web-based database will enable the dynamic tracking of evidence surrounding biomarker candidates in relation to target product profiles (TPPs) for needed TB diagnostics. It will be able to accommodate raw datasets and facilitate the verification of promising biomarker candidates and the identification of novel biomarker combinations. As such, the database will simplify data and knowledge sharing, empower collaboration, help in the coordination of efforts and allocation of resources, streamline the verification and validation of biomarker candidates, and ultimately lead to an accelerated translation into clinically useful tools.
结核病（TB）的新型诊断创新技术，包括即时检测解决方案，对于实现终结结核病战略目标至关重要。然而，尽管经过数十年研究，有大量关于新型生物标志物候选物的报告，且投入了大量资金，但市场上仍未出现性能良好、简单快速的结核病诊断检测方法，寻找准确的非DNA生物标志物仍然是优先事项。为帮助克服这一“生物标志物研发流程问题”，国际药品采购机制（FIND）及其合作伙伴正在致力于开发一个精心策划且用户友好的结核病生物标志物数据库。这个基于网络的数据库将能够动态跟踪围绕生物标志物候选物的证据，这些证据与所需结核病诊断的目标产品概况（TPP）相关。它将能够容纳原始数据集，并促进对有前景的生物标志物候选物的验证以及新型生物标志物组合的识别。因此，该数据库将简化数据和知识共享，促进合作，有助于协调工作和资源分配，简化生物标志物候选物的验证和确认流程，并最终加速转化为临床实用工具。
